Share the Video:

Patents, commons, and innovation in psychedelic drug development

Jonathan Sporn, Sisi Li, Graham Pechenik, Retsina Meyer, Anne Donohoe

As universities and companies stake intellectual property claims on psychedelic compounds, applications, and data sets, a robust dialogue has emerged about the way patents and data exclusivity may accelerate or constrain innovation, competition, and access to care. Join us for a nuanced consideration of the economic and cultural implications of intellectual property rights within the psychedelic ecosystem.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Related Videos